GW Pharmaceuticals has reported revenue growth of 67.5% for the fourth quarter, driven by demand for Epidiolex.
News
Darolutamide’s FDA rolling submission completed
Orion and Bayer have announced the completion of the rolling submission of an NDA for darolutamide.
Experimental Parkinson’s therapy shows promise
A novel experimental drug could offer hope for restoring damaged brain cells in Parkinson’s patients.
MHRA gives Nuformix’ NXP001 studies the go-ahead
The MHRA has given Nuformix approval to commence human pharmacokinetics studies with NXP001 to further assess its potential for chemotherapy-induced nausea and vomiting.
Mental health information provided to patients improving, study finds
A new study has found that information being provided to patients about their rights under the Mental Health Act has improved.
Cell Medica given $8.7 million to develop cancer therapy
Cell Medica has been awarded a $8.7 million CPRIT grant to accelerate its CMD-502 cell therapy into clinical development.
ViiV Healthcare and Radboud team up for HIV drug targets
ViiV Healthcare has announced a collaboration with The Netherland’s Radboud University Medical Centre to identify new drug targets for HIV.
Lusutrombopag gets EU green light for liver disease
Marketing authorisation in the EU has been granted for Shionogi’s lusutrombopag in severe thrombocytopenia.
Unreasonable prescription costs leading to life-threatening asthma attacks
Asthma UK has revealed that people with asthma are rationing their medication due to prescription costs.
Lynparza successful in pancreatic cancer trial
AstraZeneca and MSD’s Lynparza is the first PARP inhibitor to demonstrate a benefit in pancreatic cancer, having hit targets in the Phase III POLO trial.
Biogen & Alkermes get NDA for MS drug
The FDA has accepted the New Drug Application (NDA) for Biogen & Alkermes’ Diroximel Fumarate in multiple sclerosis (MS).
FDA Breakthrough Therapy Designation for Pompe disease drug
The FDA has granted Amicus’ AT-GAA a Breakthrough Therapy Designation (BTD) for the treatment of late onset Pompe disease.
Novartis to licence Akcea’s lipoprotein lowering drug
Novartis has announced that it is exercising its option to license the rights to develop and commercialise Akcea’s TQJ230.
Brilinta hits targets in PhIII cardiovascular/diabetes trial
AstraZeneca’s Brilinta has been found to reduce cardiovascular events in patients with coronary heart disease and diabetes but no prior heart attack or stroke.
Boehringer Ingelheim appoints new chief medical officer
Boehringer Ingelheim has announced the appointment of Dr Mehdi Shahid as chief medical officer.
